Journey Medical Corporation Common Stock
DERMJourney Medical Corporation (DERM) is a dermatology-focused biopharmaceutical company that develops and commercializes dermatology products. The company focuses on acquiring, developing, and marketing prescription and over-the-counter dermatology treatments, aiming to address unmet needs in skin health and dermatological care.
Company News
EmergingGrowth.com announced the schedule for its 85th conference featuring presentations from multiple public companies across various sectors on August 20-21, 2025, providing insights into emerging growth companies.
Journey Medical Corporation announced that the FDA has approved Emrosi™, a new treatment for inflammatory lesions of rosacea in adults. The approval is supported by positive data from the company's Phase 3 clinical trials.
SCOTTSDALE, Ariz., May 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatmen...
New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024
Company to host conference call to discuss financial results and provide a corporate update on May 13, 2024 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on May 13, 2024 at 4:30 p.m. ET
